Post-transplant HMA maintenance (oral decitabine/cedazuridine)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-16 — Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002): cross-connection with tagraxofusp-cd123-post-hct-maintenance: Tagraxofusp represents a CD123-directed alternative to HMA-based post-transplant maintenance in CD123+ MF/CMML/AML/MDS. (novelty: 3)
- 2026-06-23 — A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant: Pragmatic prospective open-label trial evaluating MRD-guided assignment of post-transplant maintenance therapy to reduce relapse in myeloid malignancies (including MPNs) undergoing allo-HCT; early trial-stage evidence, outcomes pending. (novelty: 3)
Open questions
Related
Contributing findings
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
23-jun-2026
novelty 3
per-area 3
strengthens